LDL-S3GGE* LDL-S3GGE is a Berkeley HeartLab proprietary test that measures LDL particle size as a distribution of seven subclasses. Measurements of LDL determined as part of the conventional lipid panel may be normal while LDL-S3GGE subclass analysis may indicate increased cardiovascular disease (CVD) risk.
HDL-S10GGE* HDL-S10GGE is a Berkeley HeartLab proprietary test that measures HDL particle size as a distribution of five subclasses. Standard HDL measurements may be normal while HDL-S10GGE subclass analyses may indicate increased CVD risk.
ApoB (ApoB-Ultra*) ApoB is the scientifically accepted measurement for LDL particle number. Monitoring statin therapy requires an accurate and reliable measurement of apoB.
Lp(a) Lp(a) is an inherited abnormal protein attached to LDL. Lp(a) increases coagulation and triples CVD risk.
Homocysteine Homocysteine is a metabolic by-product of methionine metabolism. Progressively elevated blood levels of homocysteine are a documented risk marker for cardiovascular events.
ApoE* Apolipoprotein E (apoE) is an inherited trait. ApoE genotype predicts lipid abnormalities and responsiveness to different dietary fat intake.
CYP2C19 Genotype Test* The FDA has placed a warning on the label of Plavix® (clopidogrel) indicating that patients who are CYP2C19 poor metabolizers may not receive the full benefits of the drug.Δ Poor metabolizers treated with Plavix at recommended doses have exhibited higher cardiovascular event rates following an acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) than patients with normal CYP2C19 function.
LPA-AspirinCheck™ Genotype Test* Recently published studies indicate that a variant of the LPA gene predicts increased CVD risk and event reduction from aspirin therapy†. The polymorphism associated with risk of CVD consists of an isoleucine residue (Ile4399) that can be replaced with a methionine residue (4399Met).^
KIF6-StatinCheck™ Genotype Test* Recent research indicates that KIF6 predicts risk of coronary heart disease (CHD) and event reduction during statin therapy‡. In large, peer-reviewed publications, statin therapy has been shown to significantly reduce the increased risk of CHD events in carriers of the KIF6 gene variant.^
9p21-EarlyMICheck™ Genotype Test* Recent research indicates that a polymorphism on chromosome 9 predicts increased risk for early onset myocardial infarction (early MI), abdominal aortic aneurysm (AAA), and MI/coronary heart disease (CHD)#. Identification of 9p21 carriers may allow health care providers to take steps to characterize and reduce risk factors that may contribute to the development or progression of disease.^
Lp-PLA2 Lp-PLA2 is a marker for vascular-specific inflammation and also plays a causal role in the vascular inflammatory process, leading to the formation of vulnerable, rupture-prone plaque. Elevated levels have been shown to be powerful predictors of ischemic stroke and heart attack risk.
hsCRP hsCRP is one of a number of acute phase reactant proteins that increases in response to inflammatory stimuli. In large epidemiologic studies, elevated levels of CRP have been shown to be a strong indicator of CVD.
Fibrinogen Fibrinogen is a plasma glycoprotein that can be transformed by thrombin into a fibrin clot in response to injury. The combination of elevated fibrinogen with other CVD risk factors can substantially increase disease potential.
Insulin Insulin is associated with the characterization of the Atherogenic Lipid Profile and Metabolic Syndrome. Abnormal fasting insulin, especially when combined with other risk factors, identifies patients at significantly higher risk for CVD.
NT-proBNP NT-proBNP is a progressive CVD risk marker with powerful independent prognostic value for detection of clinical and subclinical cardiac dysfunction. Elevated levels indicate the presence of ongoing myocardial stress and potentially an underlying cardiac disorder.
Q-LDL Atherogenic Subclass Quantitation — Q-LDL provides a measurement of atherogenic particles based upon results from apoB and LDL-S3GGE. Q-LDL is a useful monitoring metric for following response to lipid therapies particularly when pursuing aggressive LDL lowering goals.
Additional Tests Berkeley HeartLab provides: Apolipoprotein A1, Total Cholesterol, Creatine Kinase, Glucose, HDL-Cholesterol, Hemoglobin A1c, LDL-Cholesterol, Hepatic Functional Panel±, Renal Functional Panel±, Triglycerides, Thyroid Stimulating Hormone (TSH), and Uric Acid.

*This test was developed and its performance characteristics were determined by Berkeley HeartLab, a CLIA-certified and CAP-accredited laboratory. It has not been reviewed or approved by the FDA.

^ΔThe clinical impact of the CYP2C19 genotype on the metabolism of specific drugs will vary based on non-genetic factors, such as hepatic and renal status, other medications used (including over-the-counter medications, herbals, and other supplements), alcohol or illegal drug use, race, age, weight, diet, and diseases present in an individual patient.

^†Study populations predominantly consisted of Caucasian men and women 45-79 years of age.

^‡To date, the benefit of statin therapy for KIF6 carriers has only been demonstrated with atorvastatin and pravastatin therapy.

^#Study populations for early MI and MI/CHD include Caucasian and Asian men and women. Study populations for AAA include Caucasian men and women.

^{^}This genetic test may not be useful in all individuals. Supporting data may only apply to certain patient populations. Your physician may consider this test relevant for you and recommend it as part of your health management plan.

^±Components of panels can be ordered individually.